TY - JOUR
T1 - Outcomes of pregnancy and childbirth in women with hidradenitis suppurativa
AU - Sakya, Surav Man
AU - Hallan, David R.
AU - Maczuga, Steven A.
AU - Kirby, Joslyn S.
N1 - Funding Information:
The authors thank the Center for Applied Studies in Health Economics (CASHE) in the Penn State Department of Public Health Sciences for hosting the IBM MarketScan Research Databases.
Publisher Copyright:
© 2021 American Academy of Dermatology, Inc.
PY - 2022/1
Y1 - 2022/1
N2 - Background: Many women affected by hidradenitis suppurativa (HS) are of childbearing age. To date, the literature is limited on pregnancy-related outcomes for women with HS. Objective: To investigate maternal and obstetric outcomes and treatment utilization among women with HS. Methods: This retrospective analysis used the IBM MarketScan Commercial Claims Database. Pregnant women with HS (n = 998) and 5:1 age-matched pregnant women without HS (n = 5065) were identified and information on claims related to diagnoses, procedures, and medications were analyzed. Results: Compared to women without HS, pregnant women with HS had significantly lower odds of having a live birth (odds ratio [OR], 0.45; 95% confidence interval [CI], 0.39-0.51) and significantly higher odds of having elective terminations (OR, 2.51; 95% CI, 2.13-2.96), gestational hypertension (OR, 1.44; 95% CI, 1.12-1.84), and cesarean deliveries (OR, 1.28; 95% CI, 1.06-1.55), and of receiving HS designated treatment during pregnancy (OR, 4.41; 95% CI, 3.56-5.46). Limitations: Retrospective and convenience sampling and absence of clinical information to correlate HS severity and outcomes. Conclusion: Pregnant women with HS have an increased probability of select complicated maternal and obstetric outcomes. Women planning for pregnancy or who are currently pregnant may benefit from coordinated care by dermatologists and obstetric providers.
AB - Background: Many women affected by hidradenitis suppurativa (HS) are of childbearing age. To date, the literature is limited on pregnancy-related outcomes for women with HS. Objective: To investigate maternal and obstetric outcomes and treatment utilization among women with HS. Methods: This retrospective analysis used the IBM MarketScan Commercial Claims Database. Pregnant women with HS (n = 998) and 5:1 age-matched pregnant women without HS (n = 5065) were identified and information on claims related to diagnoses, procedures, and medications were analyzed. Results: Compared to women without HS, pregnant women with HS had significantly lower odds of having a live birth (odds ratio [OR], 0.45; 95% confidence interval [CI], 0.39-0.51) and significantly higher odds of having elective terminations (OR, 2.51; 95% CI, 2.13-2.96), gestational hypertension (OR, 1.44; 95% CI, 1.12-1.84), and cesarean deliveries (OR, 1.28; 95% CI, 1.06-1.55), and of receiving HS designated treatment during pregnancy (OR, 4.41; 95% CI, 3.56-5.46). Limitations: Retrospective and convenience sampling and absence of clinical information to correlate HS severity and outcomes. Conclusion: Pregnant women with HS have an increased probability of select complicated maternal and obstetric outcomes. Women planning for pregnancy or who are currently pregnant may benefit from coordinated care by dermatologists and obstetric providers.
UR - http://www.scopus.com/inward/record.url?scp=85110493672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110493672&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2021.05.059
DO - 10.1016/j.jaad.2021.05.059
M3 - Article
C2 - 34153386
AN - SCOPUS:85110493672
SN - 0190-9622
VL - 86
SP - 61
EP - 67
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 1
ER -